Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial (Q46576382)

23 December 2017

title

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial (English)

1 reference

23 December 2017

1 reference

acute coronary syndrome

1 reference

Robert Scott

8

0 references

John McMurray

2

object named as

John J V McMurray

1 reference

23 December 2017

Jean-Claude Tardif

1

object named as

Jean-Claude Tardif

1 reference

23 December 2017

author name string

Eric Klug

3

1 reference

23 December 2017

Robert Small

4

1 reference

23 December 2017

Jennifer Schumi

5

1 reference

23 December 2017

Jasmine Choi

6

1 reference

23 December 2017

Jim Cooper

7

1 reference

23 December 2017

Eldrin F Lewis

9

1 reference

23 December 2017

Philippe L L'Allier

10

1 reference

23 December 2017

Marc A Pfeffer

11

1 reference

23 December 2017

Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators

12

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

23 December 2017

published in

The Lancet

1 reference

23 December 2017

volume

371

1 reference

23 December 2017

issue

9626

1 reference

23 December 2017

page(s)

1761-1768

1 reference

23 December 2017

Atherosclerosis — An Inflammatory Disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Selective Inhibition of Endothelial and Monocyte Redox-Sensitive Genes by AGI-1067: A Novel Antioxidant and Anti-Inflammatory Agent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Effects of AGI-1067 and probucol after percutaneous coronary interventions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

A novel class of antioxidants inhibit LPS induction of tissue factor by selective inhibition of the activation of ASK1 and MAP kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Inflammation and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Prognostic associations of Minnesota Code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Hy's law: predicting serious hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Effects of probucol on xanthomata regression in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

Lowering of HDL 2b by Probucol Partly Explains the Failure of the Drug to Affect Femoral Atherosclerosis in Subjects With Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960763-1

7 January 2021

10.1016/S0140-6736(08)60763-1

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

18502300

1 reference

23 December 2017